| Chronic Fatigue Syndrome |
1 |
1 |
| Immunology |
0 |
0.99 |
| Monoclonal Antibody |
0 |
0.46 |
| Receptors |
0 |
0.46 |
| Antineoplastic Drug |
0 |
0.33 |
| Biologic Therapy |
0 |
0.3 |
| Clinical Research |
0 |
0.27 |
| Fatigue |
0 |
0.27 |
| Hospital |
0 |
0.27 |
| Autoimmune Disease |
0 |
0.8 |
| Systemic Lupus Erythematosus |
0 |
0.75 |
| Brain |
0 |
0.13 |
| Immunoglobulin G (IgG) |
0 |
0.13 |
| Plasma |
0 |
0.13 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.13 |
| COVID-19 |
0 |
0.1 |
| Antigens |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Demyelination |
0 |
0.07 |
| Dialysis |
0 |
0.07 |
| Disability |
0 |
0.07 |
| Dorsum |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Immune Thrombocytopenia |
0 |
0.07 |
| Ischemia |
0 |
0.07 |
| Lupus |
0 |
0.07 |
| Lymphoma |
0 |
0.07 |
| Major Histocompatibility Complex |
0 |
0.07 |
| Match |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Multiple Sclerosis |
0 |
0.07 |
| Neurotransmitters |
0 |
0.07 |
| Pandemic |
0 |
0.07 |
| Refractory |
0 |
0.07 |
| T-Lymphocyte |
0 |
0.07 |
| Targeted Cancer Therapy |
0 |
0.07 |
| Thrombocytopenia |
0 |
0.06 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
0 |
0.05 |
| Cardiomyopathy |
0 |
0.03 |
| Hemodialysis |
0 |
0.03 |